Metastatic HR+/HER2- Breast Cancer Therapeutics Market Size in the 7MM is projected to grow at a CAGR of 8% by 2036, estimates DelveInsight

DelveInsight's "Metastatic HR+/HER2- Breast Cancer Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Metastatic HR+/HER2- Breast Cancer, historical and forecasted epidemiology as well as Metastatic HR+/HER2- Breast Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Metastatic HR+/HER2- Breast Cancer Treatment Market Report @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Metastatic HR+/HER2- Breast Cancer Market Report
• According to the estimates, the total incident population of HR+/HER2- breast cancer in the 7MM was nearly 486,000 cases in 2025. The cases in the 7MM are expected to increase during the forecast period, i.e., 2026-2036.
• The metastatic HR+/HER2- breast cancer cases were highest in the United States, accounting for ~57,000 cases in 2025.
• According to the estimates, most cases of HR+/HER2- breast cancer occur in people aged between 60 and 79 years in the United States, accounting for ~48% of cases in 2025.
• Among EU4 and the UK, Germany had the maximum total incident cases of HR+/HER2- breast cancer, with ~50,500 cases in 2025, while Spain accounted for the least number of incident cases.
• The leading Metastatic HR+/HER2- Breast Cancer Companies include Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.
• Promising Metastatic HR+/HER2- Breast Cancer Therapies include KISQALI, PIQRAY, VERZENIO, LYNPARZA, IBRANCE, Giredestrant, Datopotamab deruxtecan (Dato-DXd), Camizestrant (AZD9833), and others.

Get a Free sample for the Metastatic HR+/HER2- Breast Cancer Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic HR+/HER2- Breast Cancer Overview
HR+/HER2- breast cancer is the most common subtype of breast cancer, characterized by cancer cells with hormone receptors for estrogen and progesterone but lacking the overexpression of HER2. This subtype generally has a better prognosis and is often treated with hormone therapy to block hormone-driven growth. Surgery and radiation may be used to remove or target tumors, while chemotherapy and targeted therapies like CDK4/6 inhibitors may be considered for more advanced cases. Early detection is crucial, and support from healthcare providers and loved ones is vital for coping with the diagnosis and treatment of HR+/HER2- breast cancer. A biopsy confirms the diagnosis and determines the cancer's characteristics. Staging tests assess the cancer's extent, guiding a multidisciplinary team in devising a personalized treatment plan, often involving hormone therapy, surgery, radiation, and possibly chemotherapy or targeted therapies. Emotional support plays a crucial role in managing the emotional toll of the diagnosis, and follow-up care ensures ongoing monitoring and adjustment of treatment as needed, fostering hope for successful recovery and survivorship.

Metastatic HR+/HER2- Breast Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of Breast Cancer
• Incident Cases of HR+/HER2- Breast Cancer
• Menopausal Status of HR+/HER2- Breast Cancer
• Stage-specific Cases of HR+/HER2- Breast Cancer
• Age-specific Cases of HR+/HER2- Breast Cancer
• Line-wise Metastatic Cases of HR+/HER2- Breast Cancer

Download the report to understand which factors are driving Metastatic HR+/HER2- Breast Cancer epidemiology trends @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic HR+/HER2- Breast Cancer Approved Therapies
• KISQALI (ribociclib): Novartis
KISQALI is a kinase inhibitor indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic cancer in combination with:
o An aromatase inhibitor as initial endocrine-based therapy
o Fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or men.
o In October 2025, Novartis announced results from the five-year analysis of the pivotal Phase III NATALEE trial of KISQALI that demonstrated a sustained benefit at a median of two years after a three-year treatment with KISQALI. Results showed a 28.4% reduction in risk of recurrence in the broadest population of patients with high-risk stage II and III HR+/HER2- early breast cancer (EBC) treated with KISQALI plus endocrine therapy compared to endocrine therapy alone.

• VERZENIO (abemaciclib): Eli Lilly
VERZENIO is a targeted treatment known as a CDK4/6 inhibitor. VERZENIO is a non-chemotherapy oral tablet. It works inside the cell to block CDK4/6 activity and help stop the growth of cancer cells so that they may eventually die (based on preclinical studies). The National Comprehensive Cancer Network (NCCN) recommends consideration of 2 years of VERZENIO added to endocrine therapy as a Category 1 treatment option in the adjuvant setting.

Metastatic HR+/HER2- Breast Cancer Pipeline Analysis
• ARV-471 (vepdegestrant): Arvinas
Vepdegestrant is an investigational, oral PROTAC estrogen receptor protein degrader for the treatment of patients with ER+/HER2- locally advanced or metastatic breast cancer. Arvinas and Pfizer are collaborating to develop and commercialize vepdegestrant. This program is currently in Phase III clinical studies. The US FDA is reviewing the filed New Drug Application (NDA) for vepdegestrant. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026. Vepdegestrant has also been granted Fast Track designation by the FDA.

• OP1250 (palazestrant): Olema Pharmaceuticals
OP-1250 is a small molecule complete estrogen receptor antagonist (CERAN). OP-1250 competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand-binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.

Metastatic HR+/HER2- Breast Cancer Companies
Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

Discover more about therapies set to grab major Metastatic HR+/HER2- Breast Cancer market share @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic HR+/HER2- Breast Cancer Market Outlook
For the past decade, endocrine therapy has been the preferred treatment for HR-positive and HER2- metastatic breast cancer, including cases with visceral involvement. This therapy, encompassing antiestrogens and aromatase inhibitors (AIs), remains the primary systemic approach for HR+/HER2- metastatic breast cancer due to its favorable treatment profile. Currently, there are three AIs available: anastrozole and letrozole are nonsteroidal AIs, while exemestane is a steroidal AI. Combining endocrine therapy with targeted agents, such as CDK 4/6 inhibitors or mTOR inhibitors, is an option for patients who do not meet the criteria for chemotherapy or sole endocrine treatment.

Metastatic HR+/HER2- Breast Cancer Treatment Market Landscape
The HR+/HER2- MBC treatment landscape comprises CDK4/6 inhibitors, SERD and SERM, and PIK3 and AKT inhibitors, each designed to target distinct mechanisms involved in tumor growth, HER2 signaling, and treatment resistance. CDK4/6 inhibitors: CDK4/6 inhibitors block cell cycle progression at the G1 phase and are widely used in HR+/HER2- metastatic breast cancer. Approved agents palbociclib, ribociclib, and abemaciclib are standard combination therapies and have generated higher revenues than mTOR inhibitors, SERDs, and other classes. SERDs: SERDs show greater benefit in endocrine-sensitive tumors, particularly those with ESR1 mutations. In January 2023, the FDA approved elacestrant (ORSERDU) for ER+/HER2-, ESR1-mutated advanced breast cancer after prior endocrine therapy. It has demonstrated a favorable safety profile compared to other agents. While some SERDs like giredestrant have shown mixed results, ongoing Phase III trials are evaluating combination strategies. PI3K and AKT inhibitors: Around 40% of HR+/HER2- breast cancers harbor PIK3CA mutations, leading to activation of the PI3K/AKT pathway involved in tumor growth. Alpelisib, combined with fulvestrant, is FDA-approved for patients with PIK3CA-mutated advanced disease based on the SOLAR-1 trial.

To know more about Metastatic HR+/HER2- Breast Cancer companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic HR+/HER2- Breast Cancer Market Report
• Study Period: 2022-2036
• Forecast Period- 2026-2036
• Coverage: 7MM
• Metastatic HR+/HER2- Breast Cancer Companies- Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.
• Metastatic HR+/HER2- Breast Cancer Therapies- KISQALI, PIQRAY, VERZENIO, LYNPARZA, IBRANCE, Giredestrant, Datopotamab deruxtecan (Dato-DXd), Camizestrant (AZD9833), and others.
• Metastatic HR+/HER2- Breast Cancer Therapeutic Assessment- Metastatic HR+/HER2- Breast Cancer current marketed and Metastatic HR+/HER2- Breast Cancer emerging therapies
• Metastatic HR+/HER2- Breast Cancer Market Dynamics: Metastatic HR+/HER2- Breast Cancer market drivers and Metastatic HR+/HER2- Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metastatic HR+/HER2- Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic HR+/HER2- Breast Cancer Market Access and Reimbursement

Table of Contents
1. Metastatic HR+/HER2- Breast Cancer Market Report Introduction
2. Executive Summary for Metastatic HR+/HER2- Breast Cancer
3. SWOT analysis of Metastatic HR+/HER2- Breast Cancer
4. Metastatic HR+/HER2- Breast Cancer Patient Share (%) Overview at a Glance
5. Metastatic HR+/HER2- Breast Cancer Market Overview at a Glance
6. Metastatic HR+/HER2- Breast Cancer Disease Background and Overview
7. Metastatic HR+/HER2- Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic HR+/HER2- Breast Cancer
9. Metastatic HR+/HER2- Breast Cancer Current Treatment and Medical Practices
10. Metastatic HR+/HER2- Breast Cancer Unmet Needs
11. Metastatic HR+/HER2- Breast Cancer Emerging Therapies
12. Metastatic HR+/HER2- Breast Cancer Market Outlook
13. Country-Wise Metastatic HR+/HER2- Breast Cancer Market Analysis (2020-2034)
14. Metastatic HR+/HER2- Breast Cancer Market Access and Reimbursement of Therapies
15. Metastatic HR+/HER2- Breast Cancer Market Drivers
16. Metastatic HR+/HER2- Breast Cancer Market Barriers
17. Metastatic HR+/HER2- Breast Cancer Appendix
18. Metastatic HR+/HER2- Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.